Literature DB >> 2876714

Aversive and appetitive properties of anxiogenic and anxiolytic agents.

S E File.   

Abstract

The place-conditioning paradigm was used to assess the appetitive or aversive nature of anxiolytic and anxiogenic drugs. Rats were given a pre-conditioning preference test in which the time that they spent on each side of a two-compartment chamber was measured; each side was visually distinct. On two days they were confined to one side immediately after drug injection, and on alternate days they were confined to the other side after vehicle injection. The rats were then given a postconditioning preference test. The change in preference was used as the measure of the reinforcing properties of the drugs. The anxiolytic drugs diazepam, lorazepam, alprazolam, adinazolam, U-43, 465 and tracazolate produced a clear preference for the drug-associated side, indicating the appetitive qualities of these drugs. Preference was less clear for the anxiolytics chlordiazepoxide and buspirone. This suggests that it is possible to dissociate the rewarding and anxiolytic properties of drugs. All the anxiogenic drugs tested (CGS 8216, picrotoxin and yohimbine) produced conditioned aversion.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2876714     DOI: 10.1016/0166-4328(86)90236-6

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  24 in total

1.  Effect of the 5-HT3 receptor antagonists, MDL72222 and ondansetron on morphine place conditioning.

Authors:  G A Higgins; N Joharchi; P Nguyen; E M Sellers
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

2.  Effect of yohimbine on reinstatement of operant responding in rats is dependent on cue contingency but not food reward history.

Authors:  Yu-Wei Chen; Kimberly A Fiscella; Samuel Z Bacharach; Gianluigi Tanda; Yavin Shaham; Donna J Calu
Journal:  Addict Biol       Date:  2014-07-27       Impact factor: 4.280

3.  The CCKB antagonist PD-134,308 facilitates rewarding effects of endogenous enkephalins but does not induce place preference in rats.

Authors:  O Valverde; M C Fournie-Zaluski; B P Roques; R Maldonado
Journal:  Psychopharmacology (Berl)       Date:  1996-01       Impact factor: 4.530

4.  Anxiogenic-like action of caerulein, a CCK-8 receptor agonist, in the mouse: influence of acute and subchronic diazepam treatment.

Authors:  J Harro; M Põld; E Vasar
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990 Jan-Feb       Impact factor: 3.000

5.  Conditioned place aversion produced by FG 7142 is attenuated by haloperidol.

Authors:  G Di Scala; G Sandner
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

6.  Effects of D-cycloserine on extinction and reconditioning of ethanol-seeking behavior in mice.

Authors:  Peter A Groblewski; K Matthew Lattal; Christopher L Cunningham
Journal:  Alcohol Clin Exp Res       Date:  2009-03-06       Impact factor: 3.455

7.  Effects of anxiogenic drugs on the emission of 22- and 50-kHz ultrasonic vocalizations in adult rats.

Authors:  Maria Willadsen; Laura M Best; Markus Wöhr; Paul B S Clarke
Journal:  Psychopharmacology (Berl)       Date:  2018-06-16       Impact factor: 4.530

8.  Benzodiazepine-induced decreases in extracellular concentrations of dopamine in the nucleus accumbens after acute and repeated administration.

Authors:  J M Finlay; G Damsma; H C Fibiger
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

9.  A re-evaluation of the role of alpha 2-adrenoceptors in the anxiogenic effects of yohimbine, using the selective antagonist delequamine in the rat.

Authors:  W S Redfern; A Williams
Journal:  Br J Pharmacol       Date:  1995-10       Impact factor: 8.739

10.  A method for conducting functional MRI studies in alert nonhuman primates: initial results with opioid agonists in male cynomolgus monkeys.

Authors:  Marc J Kaufman; Amy C Janes; Blaise deB Frederick; Melanie Brimson-Théberge; Yunjie Tong; Samuel B McWilliams; Ashley Bear; Timothy E Gillis; Katrina M Schrode; Perry F Renshaw; S Stevens Negus
Journal:  Exp Clin Psychopharmacol       Date:  2013-06-17       Impact factor: 3.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.